{"transactions":[{"id":1043894,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and Chief Scientist"}}],"security":"Stock Option (right to buy)","published_at":"2025-09-10T15:36:07.000Z","date":"2025-04-09","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued"}],"balance_after":125000,"derivative":{"exercise_price":1.7297,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001415889-25-024084","document":"form4-09102025_070903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000141588925024084/form4-09102025_070903.xml","form_type":"4"}},{"id":1326487,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and Chief Scientist"}}],"security":"Common Stock","published_at":"2024-12-18T08:27:36.000Z","date":"2024-12-17","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":1.17,"value":46800.0,"ownership":{"direct":true},"balance_after":84634,"source":{"system":"sec-edgar","filing":"0001415889-24-029694","document":"form4-12182024_011233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000141588924029694/form4-12182024_011233.xml","form_type":"4"}},{"id":1797554,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2023-08-24T12:14:01.000Z","date":"2023-08-23","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.33,"value":33000.0,"ownership":{"direct":true},"balance_after":446332,"source":{"system":"sec-edgar","filing":"0001104659-23-094815","document":"tm2324394-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000110465923094815/tm2324394-3_4seq1.xml","form_type":"4"}},{"id":1798555,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2023-08-23T09:24:41.000Z","date":"2023-08-22","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":0.322,"value":64400.0,"ownership":{"direct":true},"balance_after":346332,"source":{"system":"sec-edgar","filing":"0001104659-23-094406","document":"tm2324394-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000110465923094406/tm2324394-1_4seq1.xml","form_type":"4"}},{"id":2015903,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2023-02-14T17:14:37.000Z","date":"2022-12-14","kind":"gift","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Donation of 300,000 shares from the Jonathan Javitt Living Trust to the Jonathan Javitt Donor Advised Fund."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Charitable Transfer"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Consists of (i) 12,599,997 shares of common stock held by the Jonathan Javitt Living Trust, (ii) 1,422,000 shares of common stock held by The Javitt 2012 Irrevocable Dynasty Trust, (iii) 146,332 shares of common stock held by Jonathan Javitt individually and (iv) 300,000 held by the Jonathan Javitt Donor Advised Fund.  Jonathan Javitt is the trustee of the Jonathan Javitt Living Trust, the Grantor of The Javitt 2012 Irrevocable Dynasty Trust and the donor and primary advisor of the Jonathan Javitt Donor Advised Fund."}],"balance_after":14468329,"source":{"system":"sec-edgar","filing":"0001415889-23-002500","document":"form5-02142023_100203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000141588923002500/form5-02142023_100203.xml","form_type":"5"}},{"id":2091030,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-12-09T16:33:05.000Z","date":"2022-12-07","kind":"sale","acquired":false,"shares":400000,"price":1,"value":400000.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Private sale pursuant to an option granted by the Reporting Person in 2017 in support of a financing for NeuroRx, Inc.  Purchaser has agreed to hold the shares for a period of one year."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by the Jonathan Javitt Living Trust.  The Reporting Person is a trustee of the Trust."}],"balance_after":12899997,"source":{"system":"sec-edgar","filing":"0001415889-22-012324","document":"form4-12092022_091256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000141588922012324/form4-12092022_091256.xml","form_type":"4"}},{"id":2247247,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2022-06-02T09:46:10.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":100000,"price":0.58,"value":58000.0,"ownership":{"direct":true},"balance_after":146332,"source":{"system":"sec-edgar","filing":"0000921895-22-001874","document":"form4a13398002_06022022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000092189522001874/form4a13398002_06022022.xml","form_type":"4/A","original_submission_date":"2022-06-02"}},{"id":2247243,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2022-06-02T08:55:21.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":100000,"price":58,"value":5800000.0,"ownership":{"direct":true},"balance_after":146332,"source":{"system":"sec-edgar","filing":"0000921895-22-001872","document":"form413398002_06012022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000092189522001872/form413398002_06012022.xml","form_type":"4"}},{"id":2673767,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-10T18:48:35.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":1422000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by The Javitt 2012 Irrevocable Dynasty Trust of which the Reporting Person is the Grantor."}],"balance_after":1422000,"source":{"system":"sec-edgar","filing":"0000950142-21-001945","document":"es210157190_4-javittj.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000095014221001945/es210157190_4-javittj.xml","form_type":"4"}},{"id":2673766,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-10T18:48:35.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":13348997,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the Jonathan Javitt Living Trust of which the Reporting Person is trustee."}],"balance_after":13348997,"source":{"system":"sec-edgar","filing":"0000950142-21-001945","document":"es210157190_4-javittj.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000095014221001945/es210157190_4-javittj.xml","form_type":"4"}},{"id":2673765,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-10T18:48:35.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":46332,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed May 24, 2021, the effective date of the Merger."}],"balance_after":46332,"source":{"system":"sec-edgar","filing":"0000950142-21-001945","document":"es210157190_4-javittj.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000095014221001945/es210157190_4-javittj.xml","form_type":"4"}}]}